Although antipsychotics are established drugs in schizophrenia treatment, they are admittedly known to induce side effects favoring the onset of obesity and worsening its complications. Despite potential involvement of histamine receptor antagonism, or of other neurotransmitter systems, the mechanism by which antipsychotic drugs increase body weight is not elucidated. The aim of the present study was to investigate whether chronic antipsychotic treatments can directly alter the regulation of two main functions of white adipose tissue: lipolysis and glucose utilization. The influence of a classical antipsychotic (haloperidol) was compared to that of two atypical antipsychotics, one known to favor weight gain (olanzapine), the other not (ziprasidone). Cell size, lipolytic capacity and glucose transport activity were determined in white adipocytes of rats subjected to 5-week oral treatment with these antipsychotics. Gene expression of adipocyte proteins involved in glucose transport or fat storage and mobilization, such as glucose transporters (GLUT1 and GLUT4), leptin, matrix metallo-proteinase-9 (MMP9), hormone-sensitive lipase (HSL) and fatty acid synthase (FAS) was also evaluated. Adipocytes from chronic olanzapine-treated rats exhibited decreased lipolytic activity, lowered HSL expression and increased FAS expression. These changes were concomitant to enlarged fat deposition and adipocyte size. Alterations were observed in adipocytes from olanzapinetreated rats whereas the other antipsychotics did not induce any notable disorder. Our results therefore show evidence of an effect of chronic antipsychotic treatment on rat adipocyte metabolism. Thus, impairment of fat cell lipolysis should be considered as a side effect of certain antipsychotics, leading, along with the already documented hyperphagia, to the excessive weight gain observed in patients under prolonged treatment.
Introduction
Body weight gain is a side effect frequently observed during antipsychotic treatments, 1-3 also suspected of increasing insulin resistance and the likehood of cardiovascular complications. 4, 5 It has been suggested that antipsychotics interact with the complex systems of neurotransmitters, neuropeptides and other modulators in brain neuronal circuits like hypothalamus, solitary tract or cortical structures, to provoke disturbances in energy homeostasis and body weight control. 6 The relative antagonist properties of atypical antipsychotics for histamine H1 receptors have been reported to be a robust correlate to the rate of weight gain in treated schizophrenic patients. 3 Central administration of H1 antagonists in rats does indeed increase food intake, whereas H1 agonists decrease food intake, [7] [8] [9] indicating a role for histamine in the control of feeding behavior. In addition, antipsychotics may alter sympathetic activity, 10 and histidine, the precursor of histamine, has been reported to stimulate lipolysis in white adipose tissue via activation of the sympathetic nervous system (SNS). 11 Therefore, all these things considered, adipose tissue function appears to constitute a potential direct target of antipsychotics, at least according to their relative histamine H1 receptor antagonism. Furthermore, norepinephrine and epinephrine are key elements by which the SNS regulates thermogenesis, lipolysis and lipid oxidation, as well as adipocyte proliferation and development, via a-and b-adrenoreceptor (AR) activation. 12, 13 Antipsychotics reported to increase body weight gain have also been suspected of disrupting the SNS control of energy homeostasis by directly acting on ARs. 6, 14, 15 Many animal studies, using mainly female rats, have investigated the metabolic effects of antipsychotics, [16] [17] [18] [19] but only scarce information has been reported on adipocytes themselves during chronic antipsychotic treatments. Baptista et al. 16 did report that there was no significant change in the adipocyte number per mass unit of adipose tissue in female rats after repeated administration of the antipsychotic agents sulpiride or risperidone, but did not analyze the lipolytic or lipogenic activities in adipocytes. To our knowledge, the literature does not report any description of insulin sensitivity or of responsiveness to lipolytic agents in adipocytes isolated from antipsychotic-treated animals or patients under antipsychotic treatment.
The goal of the present study was to investigate at the cellular level the potential alteration of adipose cell size and of its lipolytic/lipogenic functional balance induced by chronic antipsychotic treatments.
To that purpose, we used a rat model of antipsychoticinduced obesity that we recently developed, 20 and which consists in feeding male rats with a diet (called P14L) enriched in carbohydrates and impoverished in proteins to a level comparable to that observed in the 'human diet' (31% fat energy, 56% glucid energy, 14% protein energy, whereas rats spontaneously eat high amounts of protein energy (35%) and small amounts of carbohydrate energy (15%)). We measured and compared the effect of a classical (haloperidol) and atypical antipsychotics (olanzapine and ziprasidone) on lipolysis and glucose transport in white adipocytes. In addition, fat pad weights and adipocyte size were measured. Gene expression of several key factors involved in trophic or metabolic adipocyte responses were also measured, such as glucose transporters (GLUT1 and GLUT4), leptin, matrix metallo-proteinase-9 (MMP9), hormone-sensitive lipase (HSL) and fatty acid synthetase (FAS). The results indicate that chronic olanzapine treatment can alter the adipocyte lipolytic responses.
Materials and methods

Animals
Male Sprague-Dawley rats (Harlan, Gannat, France) initially weighing 200-220 g were individually housed in a room maintained at 24711C and at 5575% humidity with an artificial 12:12-h light-dark cycle (lights on at 08:00). Food and water were available ad libitum throughout the experiment. All rats were fed with the P14-L diet provided by the French national institute of agronomical research (INRA, Jouy-en-Josas, France). It is composed of whole-milk protein (140 g/kg), cornstarch (538.1 g/ kg), sucrose (87.6 g/kg) and soybean oil (137 g/kg) (metabolizable energy: 17.5 kJ/g). This diet was supplemented with minerals and vitamins according to the AIN-93M requirements (mineral salts 35 g/kg; vitamins 10 g/kg; cellulose 50 g/kg; choline 2.3 g/kg). 21 This food was administered in powder form, as described previously. 20 
Antipsychotic solutions
Antipsychotics were administered by incorporation into the food. Haloperidol (Sigma-Aldrich, L'Isle d'Abeau Chesnes, France) (1 mg/kg of body weight) and olanzapine (olanzapine orally desintegrating tablets) (1 mg/kg of body weight) were solubilized in 10% ethanol and ziprasidone (Pfizer inc., NY, USA) (10 mg/kg BW) was diluted in a 10% ethanol solution. Daily food intake was measured during a period of adaptation, which made it possible to adjust the quantity of antipsychotic to be incorporated in the food.
Experimental procedure After 1 week of adaptation to environmental conditions, rats were separated into four groups (controls, haloperidol-treated, olanzapine-treated, ziprasidonetreated) according to weight, and received the antipsychotic solutions mixed with their food during 5 weeks. At the end of the study, the rats were killed by decapitation and the adipose pads dissected out for ex vivo studies.
Preparation of rat adipocytes
Adipocytes were prepared from intra-abdominal (INWAT: epididymal, perirenal, retroperitoneal fat pads) and subcutaneous inguinal white adipose tissues (SCWAT) as previously described. 22, 23 Briefly, after digestion with liberase at 371C, isolated fat cells were filtered and washed with a Krebs-Ringer buffer, pH 7.4, containing 12.5 mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 2 mM pyruvate and 3.5% (w/v) bovine serum albumin (KRH buffer). Cell suspension was immediately used for measurements of lipolysis, glucose transport and adipocyte weight and size, or rapidly frozen for RNA extraction.
Lipolysis measurements
Adipocyte suspension in KRH buffer was distributed as 400 ml portions in plastic vials and incubated at 371C with ongoing gentle shaking in the absence (basal) or in the presence of isoprenaline (b-adrenergic agonist), phenylisopropyladenosine (PIA), forskolin, 3-isobutyl-1-methylxanthine (IBMX), UK 14304 (a2-adrenergic agonist), insulin or antipsychotics at the indicated final concentrations. After 90 min, the incubation tubes were placed on ice and 150 ml of cell medium was removed for the enzymatic determination of glycerol as previously described. 24 Cell lipids were gravimetrically evaluated after extraction using the Dole and Meinertz 25 method. Results were expressed as mmol of glycerol released per 100 mg of lipid during 90 min.
Glucose transport measurement
After preincubation for 45 min at 371C with the indicated final concentrations of insulin or otherwise mentioned drugs, each vial (400 ml) received an isotopic dilution of 2-deoxy-D- [ 3 H]glucose, providing a final concentration of 0.1 mM (equivalent to approximately 1 000 000 dpm/vial). Assays were then incubated for a 10-min period and arrested with 100 ml of 100 mM cytochalasin B. The radioactivity incorporated into the fat cells was counted as described by Olefsky, 26 using dinonyl phthalate to separate intact fat cells from medium by a pulse spin as reported previously. 27 RNA preparation and real-time RT-PCR Total RNA was extracted using RNA easy minikit (Qiagen, Courtaboeuf, France). cDNA was synthesized from 1 mg of total RNA using random hexamers. We verified that the generated fluorescence was not overestimated by contaminations resulting from residual genomic DNA amplification (by using controls without reverse transcriptase) and/or from primer/ dimer formation (controls with neither DNA template nor reverse transcriptase). Gene expression was assessed with real-time PCR in an ABI PRISM 7000 Sequence Detection System instrument (Applied Biosystems, Warrington, UK) starting with 12.5 ng of reverse-transcripted total RNA as previously described. 28 The gene expression of proteins well recognized to be key elements in adipocyte biology, such as glucose transporters, GLUT1 and GLUT4, leptin, the enzymes HSL, FAS and MMP9 have been analyzed by using the previously described sets of primers. 28 Adipocyte size measurement Adipocyte suspensions were observed under a microscope connected to a camera. Three pictures from each preparation were saved and the diameter of each adipocyte was measured using Perfect Image software (Numeris, Paris, France), allowing calculation of a mean fat cell size and weight.
Statistical analysis
Results are presented as means7s.e.m. For lipolysis, glucose transport and RT-PCR, the statistical significance of differences was analyzed with Student's t-test. For adipocytes sizing, comparison of mean values between groups was evaluated by one-way analysis of variance with Tukey's multiple comparison post-test (GraphPad Sofware, San Diego, CA, USA). Differences were considered significant at P < 0.05.
Results
Adiposity at the end of treatments
Although no difference in body weight was observed between the experimental groups, adiposity was significantly increased in olanzapine-treated rats as a result of an enlargement of both subcutaneous and visceral fat pads (Table 1 ). In the epididymal fat pad of control rats, the mean weight of fat cell was calculated to average 94713 ng, and cell diameters most frequently fell between 50 and 70 mm (Figure 1 ). Mean adipocyte size and diameter distribution did not differ in haloperidol-and ziprasidone-treated rats. However, adipocytes isolated from olanzapine-treated group tended to be larger than in control, as shown in Figure 1c . A shift to the right was observed in the distribution of diameter frequency of olanzapinetreated rats. Mean adipocyte weight of olanzapinetreated animals was larger than that of controls (olanzapine: 143712 ng, control: 94714 P = 0.05) ( Figure 1 ). Food intake increased in olanzapinetreated animals without reaching significance (data not shown); the increase in food intake was parallel to the increase in body weight, similar to the results reported in our previously published experiments using the same technique. 20 Lipolytic and antilipolytic activities in adipocytes from control and antipsychotic-treated rats Basal lipolysis was unmodified in adipocytes isolated from the INWAT of antipsychotic-treated rats when compared to control. However, the dose-dependent stimulation of lipolysis induced by the b-adrenergic agonist isoprenaline was significantly weaker in the olanzapine-treated group than in the control group (Figure 2) . When considering the fold increase over basal lipolysis (set at 1), the higher dose of the badrenergic agonist (10 À5 M) resulted in an activation of 4.570.8-fold in the olanzapine-treated group, which was significantly lower than the corresponding 8.371.3 observed in the control group (P < 0.05). To Abbreviations: INWAT, intra-abdominal white adipose tissues; SCWAT, subcutaneous white adipose tissues; WAT, white adipose tissues. The mass of intra-abdominal (INWAT) or subcutaneous (SCWAT) white adipose tissues was obtained in the indicated experimental groups after 5-week treatment corresponding to a daily administration of 1 mg/kg body weight/day for haloperidol and olanzapine, and 10 mg/kg/day for ziprasidone as detailed in Materials and methods. The total mass of dissected WAT is expressed as percentage of body mass. Control n = 6, haloperidol n = 4, olanzapine n = 5, ziprasidone n = 4. Significantly different from control at *P < 0.05, **P < 0.02 and ***P < 0.01.
verify whether this alteration was a consequence of a diminished b-adrenergic responsiveness or was the reflect of a more general alteration of lipolytic capacity, the responses to other lipolytic agents were compared in adipocytes from rats treated with antipsychotics and in the controls (Figure 3 ). Lipolysis stimulation with IBMX 10 À3 M was also reduced in the olanzapine group only, whereas the response to forskolin 10 À5 M was not significantly altered whatever the group ( Figure 3) . As lipid mobilization is a balance between lipolytic and antilipolytic pathways, antilipolytic responses were also studied under similar conditions. When tested at 100 nM, insulin, the antilipolytic hormone of reference, partially inhibited the lipolytic effect of a submaximal dose of isoprenaline (10 nM) in control rats (3877% inhibition) and this antilipolytic effect was not notably modified in rats receiving haloperidol, olanzapine or ziprasidone: the respective inhibition Figure 2 Dose-response curves for isoprenaline stimulation of lipolysis in adipocytes isolated from control and antipsychotic-treated rats. Each point is the mean7s.e.m. of n determinations: control n = 5, haloperidol-treated n = 3, olanzapine-treated n = 4, ziprasidone-treated n = 4. Significantly different from the corresponding control at *P < 0.05, **P < 0.02 and ***P < 0.01.
percentage being 4375, 5878 and 5577% (Table 2) (the use of a submaximal stimulation of lipolysis is the best way to reveal potential antilipolytic effects). Similarly, the antilipolytic agent PIA (10 À6 M) partially inhibited isoprenaline-induced stimulation of lipolysis in control as well as in antipsychotic-treated rats ( Table 2 ). The a2-adrenergic agonist UK 14304 was much less efficient in counteracting the isoprenaline-induced lipolysis in control and its action was not modified in treated rats (not shown).
To further study the influence of antipsychotics on lipolysis regulation, it was tested whether they could have on their own an acute effect on adipocytes from control rats. As reported in Table 3 , none of the tested antipsychotic drugs showed any lipolytic effect. On the contrary, ziprasidone 1 mM (an elevated dose) inhibited basal lipolysis, an effect which was not mediated by its vehicle, 0.3% final dimethyl sulfoxide. Neither the tested antipsychotics nor their respective vehicles were able to alter the lipolytic effect of 10 nM isoprenaline (Table 3) .
Glucose transport in adipocytes from control and antipsychotic-treated rats Basal glucose uptake into adipocytes was not modified in the antipsychotic-treated groups when compared to control. The dose-response curves for insulin stimulation of hexose uptake were practically superimposable for all groups (Figure 4) . The maximal activation was reached with 100 nM insulin and represented a eight-to 11-fold increase over basal uptake. Vanadate was also used to stimulate glucose transport in order to test other agents than insulin. Vanadate (1 mM) partially reproduced the insulin stimulation in all groups ( Table 4 ). The synergic Figure 3 Adrenergic and nonadrenergic lipolysis stimulation in isolated adipocytes of control and antipsychotictreated rats. Significantly different from control at *P < 0.05 and ***P < 0.01. Each point is the mean7s.e.m. of four determinations in control, olanzapine-and ziprasidonetreated and three in haloperidol-treated groups. Control n = 4, haloperidol n = 3, olanzapine n = 4, ziprasidone n = 4. No significant difference between treated groups was detected regarding inhibition of isoprenaline-induced lipolysis. Abbreviation: DMSO, dimentyl sulfoxide. Data expressed as mean7s.e.m. of five determinations on adipocyte preparations of control rats. Final concentrations are indicated for all the added compounds, including vehicles. As drugs were added as a 4 ml portion in an incubation volume of 400 ml, the one-hundredth dilution of distilled water in the adipocyte suspension corresponds to basal lipolysis. No significant effect of the vehicles ethanol or DMSO detected when compared to basal or isoprenaline-stimulated lipolysis.
Significantly different from the corresponding vehicle at **P < 0.01.
Olanzapine and adipocytes gene expression J Minet-Ringuet et al combination of 0.1 mM vanadate plus 0.1 mM benzylamine clearly exhibited insulin-mimicking properties 29 and revealed no difference between control and treated groups (Table 4) . Although there was no significant difference among groups, the results nevertheless showed that the responses were always weaker in the olanzapine group.
Influence of antipsychotic treatment on gene expression in adipocytes mRNA levels of a panel of six genes were analyzed in adipocytes from control and treated rats ( Figure 5 ). The mRNAs corresponding to key elements of glucose utilization, namely the glucose transporters GLUT1 and GLUT4, did not show notable changes. The gene expression of leptin, a well-recognized adipokine, and MMP9, a protease implied in tissue remodeling and adipocyte differentiation, did not show any significant change between control and antipsychotic groups, although there was an unexplained larger variability for MMP9 mRNA in the haloperidoltreated group. By contrast, HSL and FAS gene expressions were significantly modified by olanzapine treatment, with HSL being less expressed and FAS being overexpressed. As HSL is a key element in lipolysis and as FAS is involved in lipogenesis, a reduction of the former and an increase of the latter is expected to be accompanied by an enlargement of lipid storage. The observed mRNA changes are therefore in agreement with the diminished lipolytic capacity, the increased adipocyte size and the extended fat depots reported above for olanzapinetreated rats.
Discussion
This study describes for the first time mechanisms at the adipocyte level by which antipsychotic treatments may disturb weight control and increase fat deposition. Among the antipsychotic treatments studied, only olanzapine administration decreased the lipolytic capacities of adipocytes and altered gene expression of FAS and HSL, overexpressing the former and repressing the latter. This is in agreement with the fact that only olanzapine treatment provoked a significant increase of fat mass whereas similar doses of haloperidol or higher doses of ziprasidone exhibited only a faint tendency to increase adiposity. Our results confirm previous observations of an increased fat deposition in rats under olanzapine treatment. 20, 30 And they shed more light on the mechanisms involved.
Antipsychotic effects on white adipose tissue Although no significant increase in body weight was observed in the treated rats, this study reveals that orally given olanzapine increases the development of white adipose tissue. This observation is in line with clinical studies that showed that body weight gain under olanzapine treatment was due to a specific 2-Deoxy-glucose (2DG) uptake was determined for a 10-min period in adipocytes isolated from INWAT (basal and insulin values are also presented on Figure 4 ). Each value is mean7s.e.m. of four determinations in all groups except for ziprasidone-treated (n = 3). Insulin and other compounds were incubated for 45 min before the addition of labeled 2-DG as detailed in Materials and methods. Vanadate was tested alone (1 mM) and in combination (0.1 mM) with 100 nM insulin (Van þ Ins) or with 0.1 mM benzylamine (Van þ Benz). Different from respective basal uptake at P < 0.05, **P < 0.01 and ***P < 0.001. Figure 4 Dose-response curves for insulin stimulation of glucose uptake in adipocytes isolated from control and antipsychotic-treated rats. Each point is the mean7s.e.m. of n determinations for each of the control or the treated groups: control n = 5, haloperidol n = 3, olanzapine n = 4, ziprasidone n = 4.
accumulation of white adipose tissue. 2 Furthermore, olanzapine-induced fat deposition in our study was accompanied by an increase in adipocyte weight, and possibly also by an adipocyte hypertrophy as the largest mean cell size was found in the olanzapinetreated-group. The lack of change in MMP9 expression does not favor the hypothesis of tissue remodeling with recruitment of new adipocytes, at least at this stage of fat accretion. Furthermore, the present study demonstrates that, in addition to the hyperphagia often reported under antipsychotic treatments, 17, 19, [31] [32] [33] [34] a direct alteration of the control of energy storage could be considered as another effect of antipsychotic treatments. The fact that adiposity may indeed develop without hyperphagia was suggested in a clinical study. 35 In our model, the observed increase in adiposity does not seem to be caused by an alteration of leptin secretion as gene expression of this adipokine proved unchanged between groups. This observation is in disagreement with the leptinemia disturbances observed in antipsychotic-treated patients. 36 We cannot explain the absence of increase of leptin, an observation which is at variance with our previous experiments. 30 A possible explanation could be that in the present study the body weight of the rats was unchanged.
The increased capacity of fat cells to store lipids appeared to be related to dysregulations of the genetic expression of key adipocyte enzymes. The decreased HSL expression and the increased FAS expression induced by chronic olanzapine treatment can be considered as factors explaining adipocyte hypertrophy. These alterations limit the lipolytic activity and increase the lipogenic pathways of adipocytes. Consequently, increased energy storage in the white adipose tissues (WAT) and lower fuel redistribution to the other peripheral organs may likely occur during olanzapine treatment. Lipolysis is stimulated by activation and translocation of HSL from the cytoplasmic compartment to the surface of the lipid droplets, and by phosphorylation of perilipin 37 that activates HSL activity. The decrease in adipocyte maximal lipolytic capacity shown in our study could be attributed to a limited amount of HSL rather than Figure 5 Gene expression in adipocytes from control (C, n = 5) and antipsychotic-treated rats (haloperidol H, n = 3; olanzapine O, n = 4; ziprasidone Z, n = 4). Results were expressed as arbitrary units corresponding for each gene to the mRNA abundance normalized to 18S RNA. Each column is the mean7s.e.m. of three distinct rats used for RNA extraction in each of the indicated experimental groups. Significantly different from control at ***P < 0.01 and *P < 0.05. to a dysregulation of HSL activation by perilipin, because the lack of perilipin tends to increase basal lipolysis, 38 and no difference was observed for basal lipolysis between control and olanzapine-treated groups. The determinisms for the decrease in HSL and the increase in FAS expression remain unknown and deserve further investigations that may contribute to a better understanding of adipose tissue dysfunction under antipsychotic challenge. As FAS is also expressed in hepatocytes, it would also appear critical to investigate whether liver can provide energy to the whole organism whereas WAT is sparing its lipid stores.
Alteration of lipolytic and glucose transport activities in adipocytes Differences in the pharmacological profile between ziprasidone and olanzapine are suspected to be at the origin of their widely recognized different effects on weight gain: very slight for the former and robust for the latter. 1 Similarly, the chronic effects of antipsychotics on adipocyte biology appear to depend on the nature of the antipsychotic agent. In this view, ziprasidone did not modify lipolytic responsiveness in the present model and did not alter HSL or FAS expression. Ziprasidone was also distinguishable from olanzapine in its tendency to inhibit basal lipolysis. Whether these differences indicate that, despite its tendency to slightly increase fat stores, ziprasidone could be devoid of the deleterious effects of olanzapine on glycemic control revealed in clinical studies 5, 6 remains to be established. No insulin resistance was detected in the adipocytes from antipsychotic-treated animals whether on the antilipolytic or the glucose uptake responses to the pancreatic hormone. Similarly, the insulin mimicking agents, vanadate and benzylamine, were still active in adipocytes from antipsychotic-treated animals. Such lack of insulin action impairment by antipsychotics was unexpected, as several of these drugs have been demonstrated elsewhere to develop insulin resistance, but might possibly be explained by a reversible inhibitory action alleviated during fat cell preparation. However, no effect of olanzapine on antilipolytic or glucose uptake responses was detected after chronic treatment or acute in vitro incubation.
According to Poyurovky et al., 39 the adrenergic system may be relevant to antipsychotic-induced weight gain, as the activation of the adrenergic system can attenuate antipsychotic-induced weight gain. In our study, the decrease in the lipolytic action of isoprenaline in olanzapine-treated rats might have led one to suppose that there was a reduction in the badrenergic receptivity of the adipocytes of olanzapine-treated animals. However, the reduced response to IBMX, a lipolytic agent with a mechanism of action independent from b-AR activation, together with the lack of direct inhibitory effect of olanzapine on isoprenaline-stimulated lipolysis, ruled out this hypothesis. Haloperidol, olanzapine and ziprasidone have moderate a1-and weak a2-AR antagonist properties. 40 a1-AR are not involved in lipolysis in the rat.
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Therefore a1-antagonist properties of olanzapine are unlikely involved in its antilipolysis effects. Our observations showed that the a2-adrenergic antilipolysis was very weak in adipocytes of antipsychotictreated animals, whatever be the experimental group. Thus, the a2-component is unlikely to represent the mechanism of action of antipsychotic-induced impairment of lipid mobilization. The neurotransmitter systems or receptors involved in the antilipolytic activity of olanzapine remain to be elucidated. In particular, the H1 blocking effect of olanzapine, which is not shared by haloperidol and ziprasidone, needs to be investigated. Our study of glucose transport did not evidence any clearcut alteration of insulin responsiveness at the adipocyte level. As glucose availability is critical for lipogenesis, such alteration would have impaired adipocyte replenishment and fat depot development under antipsychotic treatment. A number of studies have been recently devoted to the impairing effects of olanzapine on glucose homeostasis. The results of these studies are not unequivocal. Engl et al. 41 have shown that olanzapine impairs glycogen synthesis and insulin signaling in skeletal muscle cells. On the other hand, Robinson et al. 42 have observed that olanzapine does not affect glucose transport in in vitro preparations of adipocytes. These last results correspond to our findings. However, Vestri et al. 43 have shown that olanzapine (at a fairly high dose) decreases the maximal insulin-stimulated glucose transport rate in adipocytes. Therefore, further work is needed to determine the effects of olanzapine on glucose transport and metabolism in adipocytes. It is also possible that insulin resistance and metabolic syndrome induced by antipsychotics 5, 6 are late diabetic complications driven by exaggerated fat deposition or generated by defects in pancreatic secretion or even due to defects in insulin responsiveness in skeletal muscles or liver.
In conclusion, our study shows that the cell functions of a peripheral organ actively participating in energy homeostasis are clearly disturbed after olanzapine treatment. The adipocyte lipolysis is classically known to be stimulated by the ortho-SNS and a disorder in this autonomic pathway might be secondary to an action of certain antipsychotics on the central nervous system. However, direct long-term actions of antipsychotics on adipocyte metabolism cannot not be excluded. Although there are still missing links between olanzapine ingestion and alteration of adipocyte lipolysis, HSL and FAS gene expression, our results show for the first time that primary alterations induced by olanzapine not only include energy intake disorders but also dysregulations of lipid accumulation and mobilization. Our results indicate that the adipose tissue may be a key target of antipsychotics in relation to their undesirable side effects on the regulation of energy storage and expenditure.
